Genetically modified T-cell therapy granted enhanced EMA regulatory pathway: KTE-C19
Kite Pharma granted access to PRIME regulatory support for KTE-C19 to treat chemorefractory DLBCL In a press release, Kite Pharma announced that it is?among first sponsors selected to participate i…
